Total Payments
$8,705
2023 Payments
$198.57
Companies
8
Transactions
41
Medicare Patients
2,237
Medicare Billing
$140,334
Payment Breakdown by Category
Research$8,000 (91.9%)
Food & Beverage$692.59 (8.0%)
Education$12.74 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,000 | 2 | 91.9% |
| Food and Beverage | $692.59 | 38 | 8.0% |
| Education | $12.74 | 1 | 0.1% |
Payments by Type
Research
$8,000
2 transactions
General
$705.33
39 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $8,000 | 2 | $0 (2019) |
| ABBVIE INC. | $395.12 | 20 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $146.87 | 8 | $0 (2021) |
| Neurocrine Biosciences, Inc. | $59.81 | 4 | $0 (2022) |
| Kyowa Kirin, Inc. | $47.88 | 3 | $0 (2023) |
| Allergan, Inc. | $28.00 | 2 | $0 (2022) |
| Avion Pharmaceuticals | $14.91 | 1 | $0 (2022) |
| Mitsubishi Tanabe Pharma America, Inc. | $12.74 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $198.57 | 10 | ABBVIE INC. ($179.83) |
| 2022 | $276.67 | 16 | ABBVIE INC. ($156.01) |
| 2021 | $89.85 | 5 | AbbVie Inc. ($59.28) |
| 2020 | $109.41 | 6 | Sunovion Pharmaceuticals Inc. ($98.21) |
| 2019 | $8,018 | 3 | ACADIA Pharmaceuticals Inc ($8,000) |
| 2017 | $12.74 | 1 | Mitsubishi Tanabe Pharma America, Inc. ($12.74) |
All Payment Transactions
41 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/16/2023 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $3.90 | General |
| Category: NEUROSCIENCE | ||||||
| 10/20/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $8.80 | General |
| Category: NEUROSCIENCE | ||||||
| 10/09/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $32.54 | General |
| Category: NEUROSCIENCE | ||||||
| 07/13/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: NEUROSCIENCE | ||||||
| 07/11/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $30.92 | General |
| Category: NEUROSCIENCE | ||||||
| 07/06/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $25.90 | General |
| Category: NEUROSCIENCE | ||||||
| 07/05/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 06/27/2023 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: Adenosine A2A Receptors | ||||||
| 05/26/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $10.70 | General |
| Category: NEUROSCIENCE | ||||||
| 05/12/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $30.10 | General |
| Category: NEUROSCIENCE | ||||||
| 11/02/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $25.74 | General |
| Category: NEUROSCIENCE | ||||||
| 09/22/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: Neuropsychiatry | ||||||
| 09/13/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $27.33 | General |
| Category: NEUROSCIENCE | ||||||
| 09/13/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: NEUROSCIENCE | ||||||
| 08/11/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: Neuropsychiatry | ||||||
| 08/01/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $7.83 | General |
| Category: NEUROSCIENCE | ||||||
| 06/16/2022 | Kyowa Kirin, Inc. | NOURIANZ (Drug) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: Adenosine A2A Receptors | ||||||
| 05/10/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $27.53 | General |
| Category: NEUROSCIENCE | ||||||
| 05/04/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $11.09 | General |
| Category: NEUROSCIENCE | ||||||
| 04/22/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: Neuropsychiatry | ||||||
| 04/01/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: Neuropsychiatry | ||||||
| 03/28/2022 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: HYPERHYDROSIS | ||||||
| 03/22/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $3.73 | General |
| Category: NEUROSCIENCE | ||||||
| 03/15/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $27.88 | General |
| Category: NEUROSCIENCE | ||||||
| 02/23/2022 | Avion Pharmaceuticals | Dhivy (Drug) | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: Parkinson's disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACA 16-cAC-0001 | ACADIA Pharmaceuticals Inc | $8,000 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 465 | 491 | $125,091 | $30,567 |
| 2022 | 8 | 516 | 565 | $132,693 | $32,653 |
| 2021 | 7 | 569 | 604 | $153,222 | $36,645 |
| 2020 | 11 | 687 | 770 | $189,640 | $40,468 |
Total Patients
2,237
Total Services
2,430
Medicare Billing
$140,334
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 102 | 113 | $27,551 | $6,820 | 24.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 61 | 72 | $24,404 | $6,764 | 27.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 138 | 142 | $24,957 | $5,959 | 23.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 51 | 51 | $19,944 | $4,432 | 22.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $13,288 | $3,021 | 22.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $5,198 | $1,074 | 20.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 48 | 48 | $5,094 | $1,038 | 20.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 15 | 15 | $3,495 | $865.20 | 24.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 12 | 12 | $1,160 | $593.88 | 51.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 184 | 210 | $34,020 | $8,693 | 25.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 121 | 131 | $32,357 | $8,101 | 25.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 69 | 78 | $27,144 | $7,889 | 29.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 38 | 38 | $15,656 | $2,986 | 19.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 21 | 21 | $11,046 | $2,229 | 20.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 58 | 62 | $4,960 | $1,220 | 24.6% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 14 | 14 | $4,774 | $967.02 | 20.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $2,736 | $568.50 | 20.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 176 | 196 | $47,383 | $12,998 | 27.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 77 | 82 | $27,930 | $7,665 | 27.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 171 | 181 | $28,662 | $6,837 | 23.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 60 | 60 | $27,995 | $4,621 | 16.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 50 | 50 | $14,225 | $2,889 | 20.3% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 17 | 17 | $5,607 | $1,248 | 22.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 18 | 18 | $1,420 | $388.08 | 27.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 218 | 270 | $64,870 | $14,023 | 21.6% |
About Dr. Markos Poulopoulos, M.D
Dr. Markos Poulopoulos, M.D is a Neurology healthcare provider based in Bangor, Maine. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1922292945.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Markos Poulopoulos, M.D has received a total of $8,705 in payments from pharmaceutical and medical device companies, with $198.57 received in 2023. These payments were reported across 41 transactions from 8 companies. The most common payment nature is "" ($8,000).
As a Medicare-enrolled provider, Poulopoulos has provided services to 2,237 Medicare beneficiaries, totaling 2,430 services with total Medicare billing of $140,334. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Bangor, ME
- Active Since 09/03/2007
- Last Updated 01/31/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1922292945
Products in Payments
- NUPLAZID (Drug) $8,000
- QULIPTA (Drug) $304.66
- APTIOM (Drug) $73.46
- KYNMOBI (Drug) $73.41
- INGREZZA (Drug) $59.81
- BOTOX (Biological) $49.91
- UBRELVY (Drug) $46.19
- Nourianz (Drug) $31.91
- VRAYLAR (Drug) $22.36
- NOURIANZ (Drug) $15.97
- Dhivy (Drug) $14.91
- Radicava (Drug) $12.74
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Bangor
Enrique Feoli, M.d, M.D
Neurology — Payments: $6,994
Neurology $6,994
Carrie Downey, Do, DO
Neurology — Payments: $5,870
Neurology $5,870
Mirna Hajjar
Neurology — Payments: $1,032
Neurology $1,032
Bakhtier Nurmukhamedov, M.d, M.D
Neurology — Payments: $290.15
Neurology $290.15
Tarek Wazzan, M.d, M.D
Neurology — Payments: $200.54
Neurology $200.54
Dr. Karl Sanzenbacher, M.d, M.D
Neurology — Payments: $162.77
Neurology $162.77